Eledon Pharmaceuticals appoints Dr. Allan Douglas Kirk to board of directors

Eledon Pharmaceuticals, Inc.

Board expands from 8 to 9 directors; Dr. Kirk effective Oct 2, 2023.
Determined independent under Nasdaq rules; will serve on Science and Technology Committee.
Annual cash retainers: $42,000 for board service, $7,875 for committee service.
Granted option for 150,437 shares at market price on Oct 2, 2023; vests over 2 years.
Enters standard indemnification agreement for directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Allan Douglas Kirk

Director

ELDN · Eledon Pharmaceuticals, Inc.

Effective: 2023-10-02
Filed: October 2, 2023, 7:59 PM ET

On September 29, 2023, Allan Douglas Kirk, MD, PhD, FACS, was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 2, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Allan Douglas Kirk was appointed as Director at Eledon Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On September 29, 2023, Allan Douglas Kirk, MD, PhD, FACS, was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 2, 2023.

View on SEC.gov

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-050925

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.